X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1266) 1266
female (791) 791
male (791) 791
adult (568) 568
middle aged (554) 554
infusions, intravenous (507) 507
animals (444) 444
oncology (399) 399
injections, intravenous (396) 396
aged (389) 389
interleukin-2 - administration & dosage (388) 388
index medicus (386) 386
immunology (346) 346
interleukin-2 - therapeutic use (276) 276
interleukin-2 (270) 270
immunotherapy (268) 268
mice (248) 248
treatment outcome (242) 242
interleukin-2 - adverse effects (200) 200
cancer (191) 191
pharmacology & pharmacy (180) 180
therapy (173) 173
drug administration schedule (162) 162
immunoglobulins, intravenous - therapeutic use (152) 152
injections, subcutaneous (139) 139
rats (139) 139
lymphocytes (134) 134
adolescent (130) 130
recombinant interleukin-2 (126) 126
recombinant proteins - administration & dosage (123) 123
time factors (122) 122
cytokines (121) 121
care and treatment (118) 118
medicine, research & experimental (118) 118
dose-response relationship, drug (113) 113
antineoplastic combined chemotherapy protocols - therapeutic use (110) 110
intravenous immunoglobulin (110) 110
medicine & public health (108) 108
research (107) 107
child (105) 105
health aspects (104) 104
recombinant proteins - therapeutic use (103) 103
intravenous administration (102) 102
kidney neoplasms - drug therapy (102) 102
kidney neoplasms - therapy (95) 95
carcinoma, renal cell - drug therapy (94) 94
immunosuppressive agents - therapeutic use (94) 94
transplantation (93) 93
hematology (92) 92
chemotherapy (91) 91
expression (90) 90
surgery (89) 89
t-lymphocytes - immunology (89) 89
antineoplastic agents - administration & dosage (88) 88
t-cells (86) 86
carcinoma, renal cell - therapy (85) 85
drug therapy, combination (84) 84
interleukin-2 - pharmacology (83) 83
lymphocyte activation (83) 83
combined modality therapy (77) 77
melanoma (77) 77
melanoma - drug therapy (77) 77
cells (75) 75
melanoma - therapy (75) 75
antineoplastic agents - therapeutic use (74) 74
child, preschool (73) 73
drug therapy (72) 72
medicine, general & internal (72) 72
mice, inbred balb c (72) 72
phase-ii trial (72) 72
immunoglobulins (71) 71
kidney neoplasms - pathology (71) 71
activated killer-cells (70) 70
killer cells, natural - immunology (70) 70
antibodies, monoclonal - therapeutic use (69) 69
neoplasms - therapy (67) 67
in-vivo (66) 66
interleukin-2 - biosynthesis (66) 66
risk factors (66) 66
tumor-necrosis-factor (66) 66
flow cytometry (65) 65
infectious diseases (65) 65
mice, inbred c57bl (65) 65
research article (65) 65
t cells (65) 65
disease (64) 64
follow-up studies (63) 63
activation (62) 62
prognosis (62) 62
toxicity (62) 62
aged, 80 and over (61) 61
analysis (60) 60
antibodies (60) 60
cells, cultured (60) 60
prospective studies (60) 60
interferon-alpha (59) 59
medicine (59) 59
pediatrics (59) 59
survival (58) 58
survival rate (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1626) 1626
Japanese (16) 16
Chinese (10) 10
French (9) 9
Russian (9) 9
German (7) 7
Italian (2) 2
Danish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Abrams, D and Lévy, Y and Losso, M. H and Babiker, A and Collins, G and Cooper, D. A and Darbyshire, J and Emery, S and Fox, L and Gordin, F and Lane, H. C and Lundgren, J. D and Mitsuyasu, R and Neaton, J. D and Phillips, A and Routy, J. P and Tambussi, G and Wentworth, D and Aagaard, B and Aragon, E and Arnaiz, J and Borup, L and Clotet, B and gsted, U and Fau, A and Gey, D and Grarup, J and Hengge, U and Herrero, P and Jansson, P and Jensen, B and Jensen, K and Juncher, H and Lopez, P and Lundgren, J and Matthews, C and Mollerup, D and Pearson, M and Reilev, S and Tillmann, K and Varea, S and Angus, B and Cordwell, B and Dodds, W and Fleck, S and Horton, J and Hudson, F and Moraes, Y and Pacciarini, F and Palfreeman, A and Paton, N and Smith, N and van Hooff, F and Bebchuk, J and Denning, E and DuChene, A and Fosdick, L and Harrison, M and Herman-Lamin, K and Krum, E and Larson, G and Neaton, J and Nelson, R and Quan, K and Quan, S and Schultz, T and Thompson, G and Wyman, N and Carey, C and Chan, F and Cooper, D and Courtney-Rodgers, D and mmond, F and Harrod, M and Jacoby, S and Kearney, L and Law, M and Lin, E and Pett, S and Robson, R and Seneviratne, N and Stewart, M and Watts, E and Finley, E and Sánchez, A and Stanidge, B and Vjecha, M and Belloso, W and Davey, R and Duprez, D and Gatell, J and Hoy, J and Lifson, A and Pederson, C and Perez, G and Price, R and Prineas, R and Rhame, F and Sampson, J and Worley, J and ... and The INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee and INSIGHT-ESPRIT Study Grp and SILCAAT Sci Comm and INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee
The New England Journal of Medicine, ISSN 0028-4793, 10/2009, Volume 361, Issue 16, pp. 1548 - 1559
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2006, Volume 12, Issue 15, pp. 4619 - 4627
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 05/2019, Volume 9, Issue 1, pp. 7145 - 9
Standard-dose intravenous recombinant interleukin-2 (rIL-2) is indicated for the treatment of some subtypes of cancer; however, severe adverse events,... 
PHASE-II TRIAL | VIRUS-INFECTED PATIENTS | MULTIDISCIPLINARY SCIENCES | ACTIVE ANTIRETROVIRAL THERAPY | POSITIVE PATIENTS | DOUBLE-BLIND | THROMBOCYTOPENIA | IL-2 | TYPE-1 | RENAL-CELL CARCINOMA | T-CELLS | Thrombocytopenia | Intravenous administration | Immune response | Cytokines | Interleukin 2 | Clinical trials | Systematic review | Lymphocytes T | Thromboembolism | Patients
Journal Article
Journal of Immunotherapy, ISSN 1524-9557, 11/2013, Volume 36, Issue 9, pp. 490 - 495
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, p. e78619
The role of interleukin (IL)-15 in the pathogenesis of rheumatoid arthritis (RA) is well established; however, systemic knockdown of IL-15 receptor (IL-15R)... 
RHEUMATOID-ARTHRITIS | COLLAGEN-INDUCED ARTHRITIS | TUMOR-NECROSIS-FACTOR | MULTIDISCIPLINARY SCIENCES | IN-VIVO | IL-15 | CYTOKINE | MURINE ARTHRITIS | TNF-ALPHA | QUANTUM DOTS | FACTOR-ALPHA | Nanoparticles - chemistry | Rats, Wistar | Arthritis, Experimental - therapy | Male | Interleukin-2 Receptor beta Subunit - antagonists & inhibitors | Molecular Targeted Therapy | Interleukin-15 - biosynthesis | Interleukin-15 - immunology | Drug Carriers | Arthritis, Experimental - pathology | Hindlimb - immunology | Nanoparticles - metabolism | Polyethyleneimine - chemistry | Tumor Necrosis Factor-alpha - immunology | Interleukin-1beta - biosynthesis | T-Lymphocytes - pathology | Macrophages - immunology | Polyethyleneimine - metabolism | Macrophages - pathology | Gene Silencing | Interleukin-1beta - immunology | Rats | Arthritis, Experimental - immunology | Disease Progression | Administration, Intravenous | Animals | Hindlimb - pathology | T-Lymphocytes - immunology | RNA, Small Interfering - administration & dosage | Interleukin-2 Receptor beta Subunit - immunology | Tumor Necrosis Factor-alpha - biosynthesis | Disease | Laboratories | Pathogenesis | Genes | Interleukin | Chains | Lymphocytes T | Arthritis | Macrophages | Nanoparticles | Proteins | Biomedical materials | Interleukin 2 | Lymphocytes | Education | Rodents | Tumor necrosis factor-TNF | Life sciences | Polyethyleneimine | Cytokines | Quantum dots | Inflammation | siRNA | Interleukin 15 | Joint diseases | Ribonucleic acid--RNA | Rheumatoid arthritis | Interleukin 15 receptors | Polyethylenimine | Ribonucleic acids
Journal Article
Journal Article